Form 8-K - Current report:
SEC Accession No. 0000950170-24-121068
Filing Date
2024-11-05
Accepted
2024-11-05 07:05:07
Documents
12
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stok-20241105.htm   iXBRL 8-K 40436
2 EX-99.1 stok-ex99_1.htm EX-99.1 209831
  Complete submission text file 0000950170-24-121068.txt   377982

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20241105.xsd EX-101.SCH 24894
14 EXTRACTED XBRL INSTANCE DOCUMENT stok-20241105_htm.xml XML 4701
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 241425594
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)